The weekly litigation news digest is live. Subscribe now
Dry Powder Inhaler And Methods Of Use - EP3613421
The patent EP3613421 was granted to Aspeya on May 3, 2023. The application was originally filed on Mar 15, 2013 under application number EP19194560A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3613421
- Application Number
- EP19194560A
- Filing Date
- Mar 15, 2013
- Status
- Granted And Under Opposition
- Mar 31, 2023
- Publication Date
- May 3, 2023
- External Links
- Slate, Register, Google Patents
Patent Summary
Reducing the risk of thromboembolic events like heart attack or stroke by inhaling very low doses of aspirin using a dry powder inhaler. The doses are much lower than traditional oral aspirin, ranging from 2 mg to 10 mg. This enables faster absorption and action compared to oral aspirin due to avoiding the first pass effect in the gut. The low doses by inhalation also mitigate bleeding risks associated with higher aspirin doses.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (6) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents